Estimation of the feasibility of using empirical models for prediction of the second metachronous tumor after chemotherapy of the first tumor to improve cancer surveillance

2022

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.21294/1814-4861-2022-21-1-5-10
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Aim. To assess the possibility of using empirical models for predicting a second metachronous tumor after chemotherapy of the first one to improve the efficiency of prophylactic medical examination of cancer patients. Material and Мethods. The objects of the study are electronic databases on the chemotherapy treatment of cancer patients, extracts from the database on the treatment of patients with PM oncology for the period 1990–2015, case histories and medical records of 796 patients with metachronous PM oncology: experimental group – 496 patients after chemotherapy, control group – 300 patients after surgical treatment of the first tumor, the sample size was not previously calculated. Results. Empirical models for predicting a second metachronous tumor after chemotherapy of the first one showed the highest probability of a second metachronous tumor in three time intervals: 1256.00–1884.00 days (3.44–5.16 years; HR=2.25; tumor is 69.2 %), 3768.00–4396.00 days (10.32–12.04 years; HR=3.86; chance 79.4 %), 6280.00–6908.00 days (17, 21–18.93 years; HR=2.00; 66.7 % chance. Conclusion. Based on the results of the analysis of empirical risk models for a second metachronous tumor after chemotherapy of the first one, amendments were developed to the timing of dispensary observation of patients with primary multiple metachronous malignant neoplasms after chemotherapy of the first tumor. Knowledge of the most probable timing of the occurrence of a second metachronous tumor after chemotherapy of the first one makes it possible to more accurately draw up and, if necessary, adjust the plan for dispensary observation after chemotherapy treatment of the first tumor.